Products & Services · Deferred revenues, noncurrent
Paxlovid and Comirnaty — Deferred revenues, noncurrent
Pfizer Paxlovid and Comirnaty — Deferred revenues, noncurrent decreased by 1.2% to $816.00M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ4 2025
Last reportedQ1 2026
Rolls up toDeferred revenue, net of current portion
How to read this metric
An increase indicates long-term contractual commitments and sustained demand, while a decrease suggests a shortening of the contract duration or completion of long-term supply obligations.
Detailed definition
This represents the portion of deferred revenue for specific pharmaceutical products that is expected to be recognized a...
Peer comparison
Comparable to 'Non-current Contract Liabilities' or 'Long-term Deferred Revenue' in the pharmaceutical and medical device sectors.
Metric ID:
pfe_segment_paxlovid_and_comirnaty_deferred_revenues_noncurrentHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $826.00M | $816.00M |
| QoQ Change | — | -1.2% |
Range$816.00M – $826.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's paxlovid and comirnaty — deferred revenues, noncurrent?
- Pfizer (PFE) reported paxlovid and comirnaty — deferred revenues, noncurrent of $816.00M in Q1 2026.
- What does paxlovid and comirnaty — deferred revenues, noncurrent mean?
- The portion of advance customer payments expected to be recognized as revenue after more than one year.